Search research articles
Contact Us
Filters
Showing results (31-40 of 149) with videos related to
Page
of 15
Sort By:
European Journal of Haematology
|
November 29, 2016
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma
Massimo Offidani, Laura Corvatta, Sara Bringhen, et al.
Blood Reviews
|
January 27, 2019
Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations
Corrado Girmenia, Michele Cavo, Massimo Offidani, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
April 15, 2003
High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia
Massimo Offidani, Laura Corvatta, Riccardo Centurioni, et al.
International Journal of Cancer
|
December 3, 2013
The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2
Maria Beatrice Morelli, Massimo Offidani, Francesco Alesiani, et al.
Annals of Hematology
|
June 13, 2024
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report
Valentina Maria Manieri, Massimo Offidani, Debora Capelli, et al.
Leukemia & Lymphoma
|
December 29, 2004
Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL)
Massimo Offidani, Laura Corvatta, Lara Malerba, et al.
Cancers
|
April 14, 2025
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma
Katia Mancuso, Simona Barbato, Francesco Di Raimondo, et al.
Cancers
|
August 14, 2025
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. <i>Cancers</i> 2025, <i>17</i>, 1168
Katia Mancuso, Simona Barbato, Francesco Di Raimondo, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 30, 2010
Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials
Massimo Offidani, Pietro Leoni, Laura Corvatta, et al.
European Journal of Haematology
|
February 9, 2007
Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma
Massimo Offidani, Sara Bringhen, Laura Corvatta, et al.
Page
of 15
Search research articles
Search
Showing results (31-40 of 149) with videos related to
Sort By:
Page
of 15
European Journal of Haematology
|
November 29, 2016
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma
Massimo Offidani, Laura Corvatta, Sara Bringhen, et al.
Blood Reviews
|
January 27, 2019
Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations
Corrado Girmenia, Michele Cavo, Massimo Offidani, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
April 15, 2003
High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia
Massimo Offidani, Laura Corvatta, Riccardo Centurioni, et al.
International Journal of Cancer
|
December 3, 2013
The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2
Maria Beatrice Morelli, Massimo Offidani, Francesco Alesiani, et al.
Annals of Hematology
|
June 13, 2024
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report
Valentina Maria Manieri, Massimo Offidani, Debora Capelli, et al.
Leukemia & Lymphoma
|
December 29, 2004
Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL)
Massimo Offidani, Laura Corvatta, Lara Malerba, et al.
Cancers
|
April 14, 2025
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma
Katia Mancuso, Simona Barbato, Francesco Di Raimondo, et al.
Cancers
|
August 14, 2025
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. <i>Cancers</i> 2025, <i>17</i>, 1168
Katia Mancuso, Simona Barbato, Francesco Di Raimondo, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 30, 2010
Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials
Massimo Offidani, Pietro Leoni, Laura Corvatta, et al.
European Journal of Haematology
|
February 9, 2007
Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma
Massimo Offidani, Sara Bringhen, Laura Corvatta, et al.
Page
of 15